Volume 9, Issue 1 (3-2021)                   JoMMID 2021, 9(1): 17-24 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Karadag Gecgel S. Comparison of HBV-DNA Levels with Biochemical and Microbiological Parameters for Chronic Hepatitis Evaluation, Bursa, Turkey. JoMMID 2021; 9 (1) :17-24
URL: http://jommid.pasteur.ac.ir/article-1-322-en.html
Comparison of HBV-DNA Levels with Biochemical and Microbiological Parameters for Chronic Hepatitis Evaluation, Bursa, Turkey
Sanem Karadag Gecgel *
University of Health Sciences, Bursa Yuksek Ihtisas Training and Reseach Hospital
Abstract:   (1971 Views)
Introduction: HBV-DNA levels are used to diagnose chronic hepatitis B (CHB) disease, determine the infection phase, decide on the treatment, and determine the disease course. We aimed to compare the microbiological and biochemical parameters of patients followed up with chronic hepatitis B pre-diagnosis in our hospital according to their HBV-DNA levels. Methods: HBV-DNA levels were analyzed with the Real-Time PCR method in blood samples of 500 pre-diagnosed CHB patients between February-June 2018, retrospectively. The biochemical parameters of the patients were measured by an automatic biochemical immunoassay analyzer (Beckman Coulter DXI 800, USA), and the microbiological parameters of patients were determined by an automatic analyzer (Roche Cobas 6000, Germany). The differences between the values of biochemical and microbiological parameters of patients were determined according to HBV-DNA. Results: Mean corpuscular volume (MCV) was higher in patients with hepatitis B virus-DNA (HBV-DNA)>20000 IU/mL than patients with negative HBV-DNA, HBV-DNA<2000 IU/mL, and HBV-DNA 2000-20000 IU/mL (P<0.05, P<0.01, P<0.01). Gamma-glutamyl transpeptidase (GGT) was lower in patients with HBV-DNA ranging from 2000-20000 IU/mL than HBV-DNA negative patients, HBV-DNA<2000 IU/mL and HBV-DNA>20000 IU/mL (P<0.05). Albumin was lower in patients with  HBV-DNA>20000 IU/mL than patients with HBV-DNA 2000-20000 IU/mL and HBV-DNA<2000 IU/mL (P<0.01). Hepatitis B surface antigen (HBsAg) levels were higher in patients with HBV-DNA 2000-20000 IU/mL than HBV-DNA negative patients, and patients with HBV-DNA<2000 IU/mL and HBV-DNA>20000 IU/mL (P<0.05, P<0.05, P<0.05). Albumin was individually correlated with the HBV-DNA by 2.9%, negatively (P<0.01). Conclusion: MCV, GGT, albumin, HBsAg levels might be used as indicators to diagnose CHB disease, establish the infection phase, decide the treatment, and determine the course of the disease together with HBV-DNA levels.
Keywords: Biomarker, HBV-DNA, Hepatitis B
Full-Text [PDF 1174 kb]   (1095 Downloads)    
Type of Study: Original article | Subject: Infectious diseases and public health
Received: 2020/11/24 | Accepted: 2021/03/14 | Published: 2021/04/27
References
1. Ormeci A, Aydın Y, Sumnu A, Baran B, Soyer OM, Pınarbasi B, et al. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV-DNA levels. Int J Infect Dis. 2016; 52: 68-73. [DOI:10.1016/j.ijid.2016.09.007]
2. Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol. 2012; 57: 196-202. [DOI:10.1016/j.jhep.2011.11.030]
3. Yang HI, Lu SN, Liaw YF, You SL, Sun SA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74. [DOI:10.1056/NEJMoa013215]
4. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67 (2): 370-398.
5. Fung J, Seto WK, Lai CL, Yuen J, Wong DKH, Yuen MF. Profiles of HBV-DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy. J Hepatol. 2011; 54 (2): 195-200. [DOI:10.1016/j.jhep.2010.06.031]
6. Fung J, Yuen MF, Yuen JC, Wong DK, Lai CL. Low serum HBV-DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. Aliment Pharmacol Ther. 2007; 26 (3): 377-82. [DOI:10.1111/j.1365-2036.2007.03390.x]
7. Han SH, Tran TT. Management of Chronic Hepatitis B: An Overview of Practice Guidelines for Primary Care Providers. J Am Board Fam Med. 2015; 28 (6): 822-37. [DOI:10.3122/jabfm.2015.06.140331]
8. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen negative chronic hepatitis B - natural history and treatment. Semin Liver Dis. 2006; 26 (2): 130-41. [DOI:10.1055/s-2006-939751]
9. Chao DT, Lim JK, Ayoub WS, Nguyen LH, Nguyen MH. Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU/L and significant hepatic fibrosis. Aliment Pharmacol Ther. 2014; 39 (4): 349-58. [DOI:10.1111/apt.12590]
10. Papatheodoridis GV. Hepatitis B virus treatment: Which patients can have treatment deferred? Clin Liver Dis (Hoboken). 2013; 2 (1): 15-17. [DOI:10.1002/cld.160]
11. Karra VK, Chowdhury SJ, Ruttala R, Polipalli SK, Kar P. Clinical Significance of Quantitative HBsAg Titres and its Correlation With HBV-DNA Levels in the Natural History of Hepatitis B Virus Infection. J Clin Exp Hepatol. 2016; 6 (3): 209-15. [DOI:10.1016/j.jceh.2016.07.002]
12. Ungtrakul T, Sriprayoon T, Kusuman P, Chunnuan P, Soonklang K, Sornsamdang G, et al. Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients. Medicine (Baltimore). 2017; 96 (13): 6554. [DOI:10.1097/MD.0000000000006554]
13. Keshvari M, Alavian SM, Sharafi H. Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients. Jundishapur J Microbiol. 2015; 8 (3): e21444. [DOI:10.5812/jjm.21444]
14. Krajden M, McNabb G, Petric M. The laboratory diagnosis of hepatitis B virus. Can J Infect Dis Med Microbiol. 2005; 16 (2): 65-72. [DOI:10.1155/2005/450574]
15. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45 (2): 507-39. [DOI:10.1002/hep.21513]
16. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronichepatitis B: a 2008 update. Hepatol Int. 2008; 2 (3): 263-83. [DOI:10.1007/s12072-008-9080-3]
17. Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol. 2008; 14 (45): 6902-10. [DOI:10.3748/wjg.14.6902]
18. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther. 2010; 15 (2): 133-43. [DOI:10.3851/IMP1497]
19. Li Y, Huang YS, Wang ZZ, Yang ZR, Sun F, Zhan SY, et al. Systematic reviewwith meta-analysis: The diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. Aliment Pharmacol Ther 2016; 43: 458-69. [DOI:10.1111/apt.13488]
20. Cai J, Wang K, Han T, Jiang H. Evaluation of prognostic values of inflammation-based makers in patients with HBV- related acute-on-chronic liver failure. Medicine (Baltimore). 2018; 97 (46): e13324. [DOI:10.1097/MD.0000000000013324]
21. Mao W, Wu J. Haematologic indices in hepatitis B virus-related liver disease. Clin Chim Acta. 2020; 500: 135-42. [DOI:10.1016/j.cca.2019.10.007]
22. Jin L, Gao Y, Ye J, Zou G, Li X. Clinical Usefulness of Measuring Red Blood Cell Distribution Width in Patients with Hepatitis B Virus-Related Acute-On-Chronic Liver Failure. Clin Lab. 2017; 63 (9): 1403-10. [DOI:10.7754/Clin.Lab.2017.170301]
23. Yang J, Yan B, Yang L, Li H, Fan Y, Zhu F, et al. Macrocytic anemia is associated with the severity of liver impairment in patients with hepatitis B virus-related decompensated cirrhosis: a retrospective cross-sectional study. BMC Gastroenterol. 2018; 18: 161. [DOI:10.1186/s12876-018-0893-9]
24. Ueda T, Kawakami R, Horii M, Sugawara Y, Matsumoto T, Okada S, et al. High mean corpuscular volume is a new Indicator of prognosis in acute decompensated heart failure. Circ J. 2013; 77 (11): 2766-71. [DOI:10.1253/circj.CJ-13-0718]
25. Whicher J, Spence C. When is serum albumin worth measuring? Ann Clin Biochem. 1987; 24 (pt 6): 572-80. [DOI:10.1177/000456328702400604]
26. Walayat S, Martin D, Patel J, Ahmed U, N Asghar M, Pai AU, et al. Role of albumin in cirrhosis: from a hospitalist's perspective. J Community Hosp Intern Med Perspect. 2017; 7 (1): 8-14. [DOI:10.1080/20009666.2017.1302704]
27. Domenicali M, Baldassarre M, Giannone FA, Naldi M, Mastroroberto M, Biselli M, et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patientswith cirrhosis. Hepatology. 2014; 60 (6): 1851-60. [DOI:10.1002/hep.27322]
28. Caraceni P, Domenicali M, Tovoli A, Napoli L, Ricci CS, Tufoni M, et al. Clinical indications for the albumin use: still a controversial issue. Eur J Intern Med. 2013; 24 (8): 721-8. [DOI:10.1016/j.ejim.2013.05.015]
29. Shen J, Wen T, Li C, Yan L, Li B, Yang J. The prognostic prediction role of preoperative serum albumin level in patients with intahepatic cholangiocarcinoma following hepatectomy. Dig Dis. 2018; 36 (4): 306-13. [DOI:10.1159/000487479]
30. Witjes CD, IJzermans JN, van der Eijk AA, Hansen BE, Verhoef C, de Man RA. Quantitative HBV-DNA and AST are strong predictors for survival after HCC detection in chronic HBV patients. Neth J Med. 2011; 69 (11): 508-13.
31. Nakamuta M, Kotoh K, Enjoji M, Kajiwara E, Shimono J, Masumoto A, et al. Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients. Comp Hepatol. 2007; 6: 3. [DOI:10.1186/1476-5926-6-3]
32. Huang R, Yang CC, Liu Y, Xia J, Su R, Xiong YL, et al. Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients. World J Gastroenterol. 2015; 21 (34): 9957-65. [DOI:10.3748/wjg.v21.i34.9957]
33. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003; 39 (2): 222-30. [DOI:10.1016/S0168-8278(03)00171-5]
34. Yu Y, Fan Y, Yang Z, Lu Y, Xu Q, Chen X. Elevated serum gamma-glutamyl transferase predicts advanced histological liver damage in chronic hepatitis B. Discov Med. 2016; 21(113): 7-14.
35. Fung J, Lai CL, Fong DY, Yuen JC, Wong DK, Yuen MF. Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int. 2008; 28 (10): 1408-16. [DOI:10.1111/j.1478-3231.2008.01784.x]
36. Lei Q, Ao K, Zhang Y, Ma D, Ding D, Ke C, et al. Prognostic factors of the short-term outcomes of patients with hepatitis B virus-associated acute-on-chronic liver failure. Clinics (Sao Paulo). 2017; 72 (11): 686-92. [DOI:10.6061/clinics/2017(11)07]
37. Elefsiniotisa IS, Brokalakia H, Argyropoulosa E, Magaziotou I, Derdemezib A, Mihasa C, et al. Evaluation of liver enzymes in asymptomatic chronic hepatitis B virus infected pregnant women. Ann Gastroenterol. 2013; 26 (1): 59-65.
38. Wang HB, Wang QY, Yuan Q, Shan XY, Fu GH. Alanine aminotransferase is more sensitive to the decrease in hepatitis B virus-DNA load than other liver markers in chronic hepatitis B patients. J Clin Lab Anal. 2017; 31 (6): e22141. [DOI:10.1002/jcla.22141]
39. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology. 2012; 55 (1): 68-76. [DOI:10.1002/hep.24615]
40. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology. 2013; 57 (2): 441-50. [DOI:10.1002/hep.26041]
41. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol. 2011; 55 (5): 1121-31. [DOI:10.1016/j.jhep.2011.06.006]
42. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int. 2013; 33: 125-32. [DOI:10.1111/liv.12075]
43. Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. 2010; 55 (10): 2727-34. [DOI:10.1007/s10620-010-1179-4]
44. Lau GK. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver Int. 2010; 30 (4): 512-20. [DOI:10.1111/j.1478-3231.2009.02198.x]
45. Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int. 2009; 3 (3): 425-33. [DOI:10.1007/s12072-009-9140-3]
46. Li Q, Zhou Y, Huang C, Li W, Chen L. A novel diagnostic algorithm to predict significant liver inflammation in chronic hepatitis B virus infection patients with detectable HBV-DNA and persistently normal alanine transaminase. Sci Rep. 2018; 8 (1): 15449. [DOI:10.1038/s41598-018-33412-z]
47. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007; 47 (6): 760-7. [DOI:10.1016/j.jhep.2007.07.022]
48. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, et al. Virologic and histologic features of chronic hepatitis virus-infected asymptomatic patients with persistently normal ALT. J Gastroenterol. 2008; 134 (5): 1376-84. [DOI:10.1053/j.gastro.2008.02.075]
49. Wang HB, Wang QY, Yuan Q, Shan XY, Fu GH. Alanine aminotransferase is more sensitive to the decrease in hepatitis B virus-DNA load than other liver markers in chronic hepatitis B patients. J Clin Lab Anal. 2017; 31 (6). e22141. [DOI:10.1002/jcla.22141]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.